company background image
2696 logo

Shanghai Henlius Biotech SEHK:2696 Stock Report

Last Price

HK$23.00

Market Cap

HK$12.5b

7D

0%

1Y

91.3%

Updated

27 Aug, 2024

Data

Company Financials +

Shanghai Henlius Biotech, Inc.

SEHK:2696 Stock Report

Market Cap: HK$12.5b

2696 Stock Overview

Engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases.

About the company

2696 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth4/6
Past Performance3/6
Financial Health2/6
Dividends0/6

Rewards

Trading at 70.1% below our estimate of its fair value
Earnings are forecast to grow 11.04% per year
Became profitable this year

Risk Analysis

Has a high level of debt

Shanghai Henlius Biotech, Inc. Competitors

Shanghai Haohai Biological Technology

SEHK:6826

HK$13.7b

3SBio

SEHK:1530

HK$13.7b

Akeso

SEHK:9926

HK$40.4b

TOT BIOPHARM International

SEHK:1875

HK$1.4b

Price History & Performance

Summary of all time highs, changes and price drops for Shanghai Henlius Biotech
Historical stock prices
Current Share PriceHK$23.00
52 Week HighHK$23.45
52 Week LowHK$9.60
Beta0.81
11 Month Change2.45%
3 Month Change22.08%
1 Year Change91.35%
33 Year Change-14.50%
5 Year Changen/a
Change since IPO-53.49%

Recent News & Updates

Recent updates

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

May 25
Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Shanghai Henlius Biotech, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Mar 25
Shanghai Henlius Biotech, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Shanghai Henlius Biotech, Inc.'s (HKG:2696) Price Is Right But Growth Is Lacking

Mar 10
Shanghai Henlius Biotech, Inc.'s (HKG:2696) Price Is Right But Growth Is Lacking

Here's Why Shanghai Henlius Biotech (HKG:2696) Is Weighed Down By Its Debt Load

Dec 31
Here's Why Shanghai Henlius Biotech (HKG:2696) Is Weighed Down By Its Debt Load

The Strong Earnings Posted By Shanghai Henlius Biotech (HKG:2696) Are A Good Indication Of The Strength Of The Business

Nov 25
The Strong Earnings Posted By Shanghai Henlius Biotech (HKG:2696) Are A Good Indication Of The Strength Of The Business

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Sep 18
Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Improved Revenues Required Before Shanghai Henlius Biotech, Inc. (HKG:2696) Shares Find Their Feet

Aug 03
Improved Revenues Required Before Shanghai Henlius Biotech, Inc. (HKG:2696) Shares Find Their Feet

Shanghai Henlius Biotech (HKG:2696) Has Debt But No Earnings; Should You Worry?

May 31
Shanghai Henlius Biotech (HKG:2696) Has Debt But No Earnings; Should You Worry?

Need To Know: Analysts Are Much More Bullish On Shanghai Henlius Biotech, Inc. (HKG:2696) Revenues

Apr 06
Need To Know: Analysts Are Much More Bullish On Shanghai Henlius Biotech, Inc. (HKG:2696) Revenues

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Sep 22
Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Shareholder Returns

2696HK BiotechsHK Market
7D0%0.4%0.5%
1Y91.3%-26.4%4.4%

Return vs Industry: 2696 exceeded the Hong Kong Biotechs industry which returned -26.4% over the past year.

Return vs Market: 2696 exceeded the Hong Kong Market which returned 4.4% over the past year.

Price Volatility

Is 2696's price volatile compared to industry and market?
2696 volatility
2696 Average Weekly Movement6.7%
Biotechs Industry Average Movement7.3%
Market Average Movement6.3%
10% most volatile stocks in HK Market13.0%
10% least volatile stocks in HK Market3.3%

Stable Share Price: 2696 has not had significant price volatility in the past 3 months.

Volatility Over Time: 2696's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20103,637Jason Zhuwww.henlius.com

Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating non-hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection to treat metastatic colorectal cancer (mCRC) and recurrent non-small cell lung cancer; and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. The company also develops Serplulimab to treat squamous-cell carcinomas, gastric cancer, small cell lung cancer, hepatocellular carcinoma, metastatic colorectal cancer, solid tumors, SCCHN, sqNSCLC, hepatocellular carcinoma, and esophageal squamous cell carcinoma; HLX04-O, an anti-VEGF monoclonal antibody injection for wet age-related macular degeneration; HLX22 to treat breast and metastatic gastric cancer; HLX6018 to treat idiopathic pulmonary fibrosis; HLX07, HLX22, HLX208, HLX60, HLX42, HLX43, HLX53, and HLX51 to treat solid tumors; HLX11 to treat breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; and HLX14 to treat osteoporosis.

Shanghai Henlius Biotech, Inc. Fundamentals Summary

How do Shanghai Henlius Biotech's earnings and revenue compare to its market cap?
2696 fundamental statistics
Market capHK$12.53b
Earnings (TTM)HK$759.17m
Revenue (TTM)HK$6.19b

16.5x

P/E Ratio

2.0x

P/S Ratio

Is 2696 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2696 income statement (TTM)
RevenueCN¥5.64b
Cost of RevenueCN¥1.51b
Gross ProfitCN¥4.13b
Other ExpensesCN¥3.44b
EarningsCN¥692.34m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)1.27
Gross Margin73.23%
Net Profit Margin12.27%
Debt/Equity Ratio157.2%

How did 2696 perform over the long term?

See historical performance and comparison